OTCMKTS:ABSCF AB Science (ABSCF) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free ABSCF Stock Alerts $2.70 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.70▼$2.7050-Day Range$2.55▼$4.4652-Week Range$2.55▼$3.84VolumeN/AAverage Volume39,925 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get AB Science alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About AB Science Stock (OTCMKTS:ABSCF)AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.Read More ABSCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABSCF Stock News HeadlinesApril 26, 2024 | americanbankingnews.comAB Science S.A. (OTCMKTS:ABSCF) Short Interest Down 95.0% in AprilApril 23, 2024 | morningstar.comAB Science ABSCFApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 18, 2024 | markets.businessinsider.comAskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failureApril 4, 2024 | msn.comBrandon student off to science fair finalsApril 3, 2024 | finance.yahoo.comAB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSMarch 13, 2024 | finance.yahoo.comAB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseMarch 7, 2024 | finance.yahoo.comAB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science developmentApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 6, 2024 | finance.yahoo.comAB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the CompanyFebruary 29, 2024 | finance.yahoo.comAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETFebruary 26, 2024 | finance.yahoo.comAB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALSFebruary 23, 2024 | msn.comScience Center ranks among Top 5 USA Today's Readers' Choice Awards for 3 consecutive yearsJanuary 26, 2024 | finance.yahoo.comAB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyJanuary 15, 2024 | finance.yahoo.comAB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosisNovember 28, 2023 | finance.yahoo.comAB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell diseaseNovember 27, 2023 | finance.yahoo.comAB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”November 13, 2023 | morningstar.comAB Science ABOctober 31, 2023 | businessinsider.comThe head of AB InBev's entertainment studio has exited in the latest marketing shakeup at the Anheuser-Busch parentSeptember 29, 2023 | finance.yahoo.comAB Science today reports its revenues for the first half of 2023 and provides an update on its activitiesSeptember 25, 2023 | yahoo.comABC Moves Forward With ‘Dancing With the Stars’ Premiere After Considering DelaySeptember 25, 2023 | abcnews.go.comInterest rates will stay high 'as long as necessary': European Central Bank leaderSeptember 22, 2023 | abcnews.go.comThe U.N. system is 'sclerotic and hobbled' and needs urgent reform, top European Union official saysSeptember 18, 2023 | finance.yahoo.comAB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 14, 2023 | abcnews.go.comEuropean Central Bank raises interest rates for the 10th time in a row to fight inflation despite weak economic growthSeptember 11, 2023 | abcnews.go.comWestern Balkan heads of state press for swift approval of their European Union membership bidsSeptember 11, 2023 | abcnews.go.comEuropean Union home affairs chief appeals for release of Swedish EU employee held in Iranian prisonSee More Headlines Receive ABSCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:ABSCF CUSIPN/A CIKN/A Webwww.ab-science.com Phone(314) 720-0014FaxN/AEmployees89Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Alain Moussy MBACo-Founder, Chairman, President, CEO, MD & Scientific DirectorMr. Laurent Guy MBAChief Financial OfficerMr. Christian FASSOTTEGlobal Chief Medical OfficerMr. Alexis BERNARDHead of Veterinary SalesMr. Harshad KULKARNIHead of StatisticsDr. Albert Ahn D.V.M.President of USA OperationsMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAbacus Health ProductsOTCMKTS:ABAHFAbattis BioceuticalsOTCMKTS:ATTBFView All Competitors ABSCF Stock Analysis - Frequently Asked Questions How have ABSCF shares performed in 2024? AB Science's stock was trading at $2.55 at the beginning of 2024. Since then, ABSCF shares have increased by 5.9% and is now trading at $2.70. View the best growth stocks for 2024 here. Are investors shorting AB Science? AB Science saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 400 shares, a drop of 95.0% from the March 31st total of 8,000 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days. View AB Science's Short Interest. How do I buy shares of AB Science? Shares of ABSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ABSCF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AB Science S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
